Cybin to Participate in the Cantor Global Healthcare Conference 2025

TORONTO –(BUSINESS WIRE)–Sep. 3, 2025– Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today

Cybin Announces Senior Leadership Changes

Doug Drysdale to step down as Chief Executive Officer; Eric So appointed Interim Chief Executive Officer    This news release constitutes a “designated news release” for the purposes of Cybin’s prospectus supplement dated February 10, 2025 , to its short form base shelf prospectus dated August 17,

Cybin Announces Results of Annual Meeting of Shareholders

TORONTO –(BUSINESS WIRE)–Aug. 18, 2025– Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthcare by developing new and innovative next-generation treatment options, is pleased

Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference

TORONTO–(BUSINESS WIRE)–  Cybin  Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce